evaluate the pharmaceuticals company wegovy on glp-1 efficacy / effectiveness FDA has approved the first pill for weight loss, a milestone in the growth of the revolutionary drugs. The drug, a once-a-day tablet, is also approved for reducing cardiovascular The Big Trial of a

The STEP 1 trial showed semaglutide 2.4 mg led to 14.9% weight loss over 68 weeks, while SURMOUNT-1 showed tirzepatide achieved up to 20.9% weight reductionapproaching bariatric surgery outcomes.[6] The SELECT trial (17,604 patients) found semaglutide reduced cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% and all-cause mortality by 19%, suggesting direct cardioprotective effects beyond weight loss.[4] In STEP-HFpEF, semaglutide produced 13.3% weight loss in heart failure patients and improved symptoms and physical function

The data didnt lie

Moreover, rimonabant use was associated with several improved metabolic markers including glycaemic and lipid control [103]

Tirzepatide : This peptide is unique because it targets both GLP-1 and GIP receptors, enhancing its effects on fat metabolism and insulin sensitivity